CNTB Stock Overview
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on developing therapies to treat T cell-driven inflammatory diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Connect Biopharma Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.67 |
| 52 Week High | US$2.84 |
| 52 Week Low | US$0.53 |
| Beta | -0.60 |
| 1 Month Change | 28.46% |
| 3 Month Change | 62.15% |
| 1 Year Change | 53.21% |
| 3 Year Change | -90.31% |
| 5 Year Change | n/a |
| Change since IPO | -90.97% |
Recent News & Updates
Recent updates
Companies Like Connect Biopharma Holdings (NASDAQ:CNTB) Are In A Position To Invest In Growth
Mar 07
Is Connect Biopharma Holdings (NASDAQ:CNTB) In A Good Position To Invest In Growth?
Sep 19Will Connect Biopharma Holdings (NASDAQ:CNTB) Spend Its Cash Wisely?
Mar 29Is Connect Biopharma Holdings (NASDAQ:CNTB) In A Good Position To Deliver On Growth Plans?
Dec 14Market Appears To Relegate Connect Biopharma To A Long-Term Hold
Oct 10Connect Biopharma Is A Sleeper Heading Into October Data Readout
Sep 26Connect Biopharma reports 1H results
Sep 13We're Keeping An Eye On Connect Biopharma Holdings' (NASDAQ:CNTB) Cash Burn Rate
Aug 12We're Keeping An Eye On Connect Biopharma Holdings' (NASDAQ:CNTB) Cash Burn Rate
Apr 29Connect Biopharma's Latest Dermatitis Drug Update Fails To Pump Up Shares
Jan 12We're Hopeful That Connect Biopharma Holdings (NASDAQ:CNTB) Will Use Its Cash Wisely
Jan 01Shareholder Returns
| CNTB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.2% | -3.9% | -3.1% |
| 1Y | 53.2% | -1.8% | 20.9% |
Return vs Industry: CNTB exceeded the US Biotechs industry which returned -0.2% over the past year.
Return vs Market: CNTB exceeded the US Market which returned 22.4% over the past year.
Price Volatility
| CNTB volatility | |
|---|---|
| CNTB Average Weekly Movement | 20.2% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CNTB's share price has been volatile over the past 3 months.
Volatility Over Time: CNTB's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 100 | Zheng Wei | www.connectbiopharm.com |
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on developing therapies to treat T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is CBP-201, an antibody to target interleukin-4 receptor alpha in development for the treatment of atopic dermatitis (AD) and asthma.
Connect Biopharma Holdings Limited Fundamentals Summary
| CNTB fundamental statistics | |
|---|---|
| Market cap | US$94.72m |
| Earnings (TTM) | -US$83.96m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.1x
P/E RatioIs CNTB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CNTB income statement (TTM) | |
|---|---|
| Revenue | CN¥0 |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥0 |
| Other Expenses | CN¥607.73m |
| Earnings | -CN¥607.73m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -11.04 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CNTB perform over the long term?
See historical performance and comparison